REGN1033
Trevogrumab (REGN1033)
N/A Amino Acids · MW: ~150 kDa
Amino Acids
N/A
Molecular Weight
~150 kDa
Half-life
~2-3 weeks
Research Score
4.3
Studies
60
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is REGN1033?
A human monoclonal antibody that neutralizes myostatin, the key negative regulator of skeletal muscle growth. It has been evaluated for muscle loss states and as a body-composition modulator in combination regimens.
Key Benefits & Mechanisms
myostatin blockade
lean-mass preservation
muscle hypertrophy support
catabolic-state countermeasure
Research Summary
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
Related Peptides
FS315
Follistatin-315 (FS315)
The circulating major isoform of follistatin that binds activins and can modulate myostatin signaling. It is widely used in research because it is the more common endogenous secreted form in human plasma.
Muscle & PerformanceACE-031
ACE-031 (soluble activin receptor type IIB-Fc)
A recombinant decoy receptor fusion protein that traps myostatin and related ligands such as activins. It was developed to promote skeletal muscle growth and counteract wasting.
Muscle & PerformanceBYM338
Bimagrumab (BYM338)
A human monoclonal antibody against activin type II receptors that blocks myostatin/activin signaling at the receptor level. It has been studied for sarcopenia, obesity with muscle preservation, and several wasting conditions.
Muscle & PerformanceEpoetin Alfa
Recombinant human erythropoietin alfa
Recombinant human erythropoietin alfa is a glycoprotein hormone that stimulates red blood cell production. In endurance contexts, its main effect is improving oxygen delivery and potentially raising VO2 max, but the safety margin is narrow.
Muscle & Performance